New To DesiZip?
  Forgot Password?
Become DESIZIP Agent & Make More Money. Everything For FREE!!!
                                               
Home Classifieds Matrimonial News Jobs Gallery Events Properties Yellow Pages Forum Agents
          Country News  |  State News  |  City News  |  Zip News  |  News By Media  |  News In Picture  |  Search
 
  By Category
 
 
Budget
Cricket
Culture
Entertainment
Health
Money
Others
Politics
Sports
Technology
Travel
Weather
Events
 
  India On Media
 
 
 
BBC
Bloomberg
Reuters
 
Health News

2 Experimental Ebola Vaccines Appea
2 Experimental Ebola Vaccines Appear Safe Says United States Agency
 UNITED STATES OF AMERICA , 27-March-2015  13:9:13 PM
Two experimental Ebola vaccines, tested in Liberia on more than 600 people in a phase 2 clinical trial appear to be safe, the US National Institute of Allergy and Infectious Diseases (NIAID) said Thursday.

The results confirm two clinical trials, each with some 20 people, that were carried out earlier in the United States.

The current, unprecedented epidemic of the disease has killed more than 10,000 people since it first emerged in early 2014 in west Africa, mainly in Liberia, Sierra Leone and Guinea.

RelatedEbola-Hit Sierra Leone Delays School Reopening

A Year After Ebola Discovered, Relapses Seen in Fight to End it

Slow Ebola Response Cost Thousands of Lives: Medical Agency

The two new vaccines are known as VSV-EBOV, developed by the British company GlaxoSmithKline and the NIAID, and VSV-ZEBOV, developed by the Public Health Agency of Canada and licensed to NewLink Genetics and Merck, both American firms.

The test is continuing by raising the number of subjects to around 1,500 people, and also to include a higher proportion of women, which is currently about 16 percent, the US agency said in a statement. The test is aimed at determining how effective the vaccines are.

There will be a follow-up period of at least one year. Two more blood samples will be taken from all volunteers at six and 12 months post-vaccination to ascertain how durable the immune responses are.

Researchers had planned to enlist 27,000 people in Liberia at risk of Ebola, such as health care workers, for the phase 3 portion of the trial.

But in Liberia there has been only one new confirmed case of the disease since February 19 of this year. So the leaders of the trial have decided to explore the possibility of extending the testing to other sites in other west African countries where infections continue to emerge.

.

From : http://www.ndtv.com  

Posted By : Desi

ADVERTISEMENTS

Free offer!!! Become an administrator for your zip home page, "Post" local news (local to your postcode)& pictures, "Post" advertisement banners from local companies. Make Extra money.

 
 
Home  |  Classifieds  |  Matrimonial  |  Yellow Pages  |  Jobs  |  Resumes  |  Events  |  Properties  |  Movies
Forum  |  About Us  |  Contact Us  |  Feedback  |  Help  |  Useful Links |  Advertise With Us  |  Site Map
                  See Terms and Conditions,
                  © 2016-2017 Copyright @ Desizip, All Rights Reserved.